drugset

drugset / Trial / NCT06544109

Venetoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia Patients

NCT06544109 ↗

Phase 2/3 Enrolling by invitation 98 enrolled The First Affiliated Hospital of Soochow University

NaSingle-groupOpen-labelPrevention

Summary

This study is to assess the efficacy and safety of venetoclax for prevention of DS in APL patients undergoing ATRA/ATO induction regimen.

Timeline

Start: 2023-08-01
Primary completion: 2025-08-01
Completion: 2028-08-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Venetoclax	Small molecule	—	—

Indications